Skip to main content
FARON PHARMACEUTICALS OY logo

FARON PHARMACEUTICALS OY — Investor Relations & Filings

Ticker · FARN ISIN · FI4000153309 LEI · 7437009H31TO1DC0EB42 IL Manufacturing
Open in API
Filings indexed 629 across all filing types
Latest filing 2025-02-11 Board/Management Inform…
Country FI Finland
Listing IL FARN

About FARON PHARMACEUTICALS OY

https://faron.com/

Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer. The company pioneers macrophage-targeting therapies to leverage the patient's immune system, aiming to address unmet medical needs and improve outcomes. Its lead asset, bexmarilimab, is a first-in-class anti-Clever-1 antibody and a myeloid cell-targeting immunotherapy candidate. Bexmarilimab is being investigated in clinical trials as a potential therapy for hematological malignancies and solid tumors, often in combination with standard-of-care treatments.

Recent filings

Filing Released Lang Actions
Change of Broker
Board/Management Information Classification · 99% confidence The document is a short announcement disseminated via RNS (Regulatory News Service) from the London Stock Exchange. It announces a specific corporate action: the 'Change of Broker' for Faron Pharmaceuticals Ltd., replacing Peel Hunt LLP with Cairn Financial Advisers LLP. This type of specific, non-financial, operational update that is distributed through official regulatory channels but doesn't fit into major categories like 10-K, ER, or DIV, is best classified as a general Regulatory Filing (RNS). The document length is very short (2093 chars), supporting the idea that it is an announcement rather than a comprehensive report.
2025-02-11 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is identified by the RNS Number (2288W) and contains the header 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, specifically detailing the acquisition or disposal of voting rights and the resulting percentage held by an individual (Timo Syrjälä). This directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the content is highly specific to share ownership changes, making MRQ the most accurate classification over the general RNS fallback.
2025-02-06 English
Results of Oversubscribed Placing
Capital/Financing Update Classification · 95% confidence The document is an RNS (Regulatory News Service) announcement dated February 6, 2025, detailing the results of a 'Placing' (share issuance/fundraising). Key phrases include 'Announcement of the Results of the Significantly Oversubscribed Placing,' 'raise gross proceeds of EUR 12 million,' 'issuance of 6,976,744 Placing Shares,' and 'registration of Placing Shares with the Trade Register.' This announcement concerns a capital raising/financing activity. While it relates to capital structure changes (CAP), the primary function of this specific RNS filing is to announce the successful completion and details of the fundraising effort, which falls under the broader category of Capital/Financing Update (CAP). However, since the document is a formal regulatory announcement (RNS Number: 0938W) detailing a significant corporate action (share issuance/fundraising), and the definitions provided include 'Capital/Financing Update (Code: CAP)' for fundraising activities, CAP is the most precise fit for the *content* of the announcement. If the document were merely announcing that a CAP document was available, RPA or RNS would apply, but this document *is* the detailed announcement of the capital raise itself. Given the focus on raising capital and issuing shares, CAP is appropriate, although RNS is the delivery mechanism.
2025-02-06 English
Proposed Issue and Placing
Capital/Financing Update Classification · 98% confidence The document is an official announcement dated February 5, 2025, from Faron Pharmaceuticals Ltd. It details a 'Proposed Issue and Placing of preliminarily approx. EUR 10 million by way of an accelerated book-building.' This describes a specific corporate financing activity aimed at raising capital through the issuance of new shares to institutional investors. This directly matches the definition for Capital/Financing Update (CAP). Although it is a regulatory filing (RNS), the content is highly specific to a financing event, making CAP the most precise classification. It is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report (RPA).
2025-02-05 English
Final Patient Identified for BEXMAB Phase II Study
Earnings Release Classification · 99% confidence The document starts with an RNS Number and is dated January 31, 2025. The content is a press release announcing a clinical trial milestone ('Faron Announces Final Patient Identified for the BEXMAB Phase II Study') and providing updates on efficacy data timelines. It is not a full financial report (like 10-K or IR), nor is it a formal regulatory filing like a Director's Dealing or Major Shareholding Notification. It is a specific, time-sensitive announcement disseminated via the RNS system, detailing operational and clinical progress. Since it is a general regulatory announcement disseminated through the RNS service that doesn't fit the more specific categories (like ER, DIV, CAP, etc.), the most appropriate classification is the general regulatory announcement category, RNS. Q1 2025
2025-01-31 English
Faron’s Financial Calendar for 2025
Report Publication Announcement Classification · 100% confidence The document is a short announcement (3246 characters) released via RNS (RNS Number : 9181P) from Faron Pharmaceuticals Ltd. The core content is the announcement of the company's Financial Calendar for 2025, specifically listing the dates for the 'Financial statement release for the full year 2024 and Annual Report 2024' and the 'Half-year financial report'. It also mentions the planned date for the Annual General Meeting. Since this document is merely announcing the dates and existence of future reports (like the Annual Report and Half-year report) rather than containing the full content of those reports, it fits the definition of a Report Publication Announcement (RPA). It is not the full 10-K, IR, or ER itself. The presence of the RNS header and footer strongly supports this classification.
2024-12-13 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.